Nemonoxacin is under clinical development by TaiGen Biotechnology and currently in Phase III for Urinary Tract Infections. According to GlobalData, Phase III drugs for Urinary Tract Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nemonoxacin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nemonoxacin overview
Nemonoxacin (Taigexyn, Wingard) is a non-fluorinated quinolone antibiotic. It is formulated as hard gelatin capsules for oral route of administration. Taigexyn is indicated for the treatment of community-acquired pneumonia. Taigexyn also shown activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA as well as quinolone-resistant Streptococcus pneumonia.
TaiGen Biotechnology overview
TaiGen Biotechnology, a subsidiary of TaiGen Biopharmaceuticals Holdings Ltd, is a research-based pharmaceutical company that develops novel therapeutics for infectious diseases, cancer, and diabetes-related complications. The company’s pipeline products include nanofloxacin, brishafo, vlarevir and TG-1000. Its nemonoxacin is a non-fluorinated quinolone antibacterial for community acquired pneumonia, diabetic foot infection and other indications. TaiGen Biotechnology has products under development for the treatment of various conditions such as solid tumors, hematological cancers, and others. The company works in partnership with other research institutes, hospitals and pharmaceutical companies. It researches anti-influenza drug and anti-gram negative bacteria drug. TaiGen Biotechnology is headquartered in Taipei, Taiwan.
For a complete picture of Nemonoxacin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
